Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methodology in anti-emetic trials.

R J Gralla1, R A Clark, M G Kris

  • 1Ochsner Cancer Institute, New Orleans, Los Angeles.

European Journal of Cancer (Oxford, England : 1990)
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

ESMO open·2026
Same author

Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Deciphering radiological stable disease to immune checkpoint inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

COVID-19 in patients with lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Accurate assessment methods have significantly improved control of chemotherapy-induced emesis. Proper study design and evaluation techniques are crucial for identifying effective anti-emetic treatments.

Area of Science:

  • Oncology
  • Clinical Pharmacology

Background:

  • Chemotherapy-induced emesis is a significant challenge in cancer care.
  • Advances in anti-emetic therapies have improved patient outcomes over the last decade.

Purpose of the Study:

  • To outline key areas for evaluating anti-emetic studies.
  • To emphasize the importance of robust methodology in clinical trials for emesis control.

Main Methods:

  • Review of factors critical for effective anti-emetic study design.
  • Emphasis on standardized patient, chemotherapy, and anti-emetic variables.
  • Highlighting the need for reliable and valid methods for assessing nausea and emesis.

Main Results:

  • Accurate assessment methodology is a key factor in improved emesis control.

Related Experiment Videos

  • Proper study design facilitates the identification of active anti-emetic agents and combinations.
  • Standardization and reliable evaluation techniques enhance the validity of study findings.

    • Conclusions:

    • Rigorous methodology is essential for advancing the control of chemotherapy-induced emesis.
    • Well-designed trials with appropriate statistical considerations lead to more effective anti-emetic strategies.
    • Continued focus on methodological improvements will further optimize anti-emetic therapy.